Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-10-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerrandomizationcellnsclcradiation
  Phrases that lowered it: patients whothe trialpatients withclinicalinvestigator
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 32.5% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Phase: 2 (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 13 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 97.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 532 (raises risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Drug's FAERS reports before start: 2091 (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer NCT03801304 · started 2019 · scored riskier than 87% of active trials completed
• Trial of Poor Performance Status Patients (ToPPS) NCT00892710 · started 2009 · scored riskier than 68% of active trials completed
• Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer NCT02679963 · started 2016 · scored riskier than 98% of active trials terminated
• Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC NCT02504489 · started 2015 · scored riskier than 77% of active trials completed
• Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations NCT00891579 · started 2009 · scored riskier than 95% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.